Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Myelodysplastic Syndromes 8Myeloproliferative Disorders 4Lymphoma 4Leukemia 4Graft vs Host Disease 4Lymphoma, Non-Hodgkin 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Hodgkin Disease 3Burkitt Lymphoma 3Primary Myelofibrosis 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Biphenotypic, Acute 2Hematologic Neoplasms 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Blast Crisis 2Anemia, Refractory, with Excess of Blasts 2beta-Thalassemia 1Waldenstrom Macroglobulinemia 1Thrombocythemia, Essential 1Thalassemia 1Sezary Syndrome 1Recurrence 1Pseudomyxoma Peritonei 1Precancerous Conditions 1Polycythemia Vera 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1

Interventions

thymoglobulin 1luspatercept 1fludarabine 1Tacrolimus 1Rituximab 1Mycophenolic Acid 1Dexamethasone 1Cyclophosphamide 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
beta-Thalassemia × Tacrolimus × 30 days × Clear all
NCT05736419 2026-06-03

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
24 enrolled
Classical hematology

Anemia, Sickle Cell, Thalassemia, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡